“…Experimental studies indicate that the administration of Celecoxib at a concentration of 1000 ppm decreases microvascular density, also reducing the presence of VEGF in multidrug-resistant TA3 tumor cells, which would make it a good candidate for use alone, or in combination with other anti-tumor molecules, ideally with the aim of obtaining synergistic effects (Rosas et al, 2014). For their part, Roa et al (2017) indicate that the CX/PLGA association inhibits microvascularization, VEGF expression at the tumor level, as well as cell proliferation and increased apoptosis. On the other hand, it has been shown that Celecoxib reduces serum levels of VEGF and COX-2 (Han et al, 2014), which would explain the decrease in vascularization, knowing that VEGF is the most critical factor associated with vasculogenesis, angiogenesis and lymphangiogenesis, VEGF-A being an essential regulator of angiogenesis, acting mainly by promoting cell division and migration in endothelial cells (Oklu et al, 2010).…”